凉血疏肝方治疗雌激素受体阳性乳腺癌术后患者的疗效分析

Clinical Study of Efficacy of Liangxue Shugan Decoction for Estrogen Receptor Positive Patients with Breast Cancer after Surgery

目的探讨凉血疏肝方对雌激素受体阳性乳腺癌术后患者的影响。方法选取80例经病理检查证实为雌激素受体阳性乳腺癌术后的患者,按照治疗方案将患者分成两组(每组各40例),对照组予以枸橼酸他莫昔芬片治疗,观察组在治疗组的基础上加用凉血疏肝方治疗,观察两组患者治疗前后雌二醇水平和子宫内膜厚度,治疗后两组患者血细胞分析、肝功能、肾功能有无异常,治疗3个月后是否出现复发转移。结果治疗前两组患者雌二醇水平比较无差异[(243.78±54.50)pmol/L vs(252.16±63.35)pmol/L](P>0.05);治疗后观察组雌二醇水平明显高于对照组[(128.44±56.34)pmol/L vs(145.97±59.39)pmol/L](P<0.05);治疗前两组患者子宫内膜厚度比较无差异[(5.22±1.65)mm vs(5.86±1.76)mm](P>0.05),治疗后对照组子宫内膜厚度明显增厚(P<0.05),观察组子宫内膜厚度变薄(P<0.05),两组患者比较有差异[(4.27±1.43)mm vs(7.74±1.48)mm](P<0.05);两组均未出现严重的骨髓抑制、肝功能异常及肾功能异常,并且均未出现乳腺癌转移复发的情况。两组患者不良反应比较差异有统计学意义(χ~2=6.135,P=0.013)。结论凉血疏肝方能有效减轻枸橼酸他莫昔芬治疗引起的副作用,并且无明显毒副作用,值得在临床上推广使用。

Objective To investigate the efficacy of Liangxue Shugan decoction for estrogen receptor positive patients with breast cancer after surgery. Methods 80 patients with pathologically confirmed estrogen receptor positive breast cancer were divided into the control group and the observation group according to the treatment regimen, each with 40 cases. The control group were given tamoxifen citrate tablets treatment and the observation group were given Liangxue Shugan decoction on the basis of the control group. The levels of estradiol, endometrial thickness were observed before and after therapy and the blood cells,liver func- tion, kidney function without exception,whether metastasis of breast cancer recurrence after 3 months of treatment were observed and compared between the 2 groups. Results The levels of estradiol in the 2 groups before treatment showed no difference [ （243.78 ± 54.50） pmol/L vs （252.16 ±63.35） pmol/L] （P 〉0.05）. After treatment,the estradiol level in the observation group was significantly lower than that of the control group [ （ 128.44 ± 56.34） pmol/L vs （ 145.97 ± 59.39） pmol/L] （P 〈 0.05 ）. The endometrial thickness between the 2 groups of patients before treatment had no significant difference[ （5.22 ± 1.65 ） mm vs （ 5.86 ± 1.76 ）mm ] （ P 〉 0.05 ）, and after treatment, the control group was significantly thicker than before treatment （ P 〈 0.05 ）, the observation group was thinner （ P 〈 0. 05 ） , there were differences between the 2 groups [ （4.27 ± 1.43 ） mm vs （7.74 ± 1.48 ） mm] （ P 〈 0.05 ）. There were no severe bone marrow suppression, liver dysfunction and renal dysfunction, and there had no breast cancer metastasis and recurrence. The adverse events between the 2 groups had statistically significant differ- ences （x^2 = 6. 135 ,P =0.013）. Conclusion Liangxue Shugan decoction in the treatment of estrogen receptor-positive patients with breast cancer after surgery can significantly reduce the side effects caused by tamoxifen citrate therapy, without significant -side effects, which is worthy of clinical application.